A single dose of CB-010 resulted in profound tumor regression of metastatic CD19+ tumor xenografts and led to a significantly longer antitumor response and survival vs. conventional CD19-specific allogeneic CAR-T cells (expressing PD-1) | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------|-------|-------|-------|-------|-------|---------------------|-------|-------| | PBS (negative control) | | | | | | 100 | | | | CD19 CAR-T (PD-1 positive) | | | | | | Percent survival 50 | ...